When Mike Scanlon set out on a 30-day, 700-mile bike ride across Kansas, the journey ahead of him was daunting. He had 60 trails, 50 towns, and what felt like endless gravel roads ahead of him. But for Mike, [...]
June and Roy Smoot June & Roy live in Kennebunk, Maine, a place they moved after visiting and vacationing many times throughout their lives. They enjoy barefoot beach walks, snowshoeing, many volunteer activities focused on environmental issues, [...]
By Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer Hearing that cancer has spread to the brain or spinal cord can be a frightening, but very real outcome for many people living with lung cancer. While exact statistics are hard to pin down, recent studies suggest that about 10-40% of lung [...]
The start of a new year is a great time to take a fresh look at your health insurance. Many insurance benefits reset in January, which means you may have new chances to get care at a lower cost. [...]
Today marks a huge step for improving the lives of everyone affected by lung cancer. S. 1157, the Women and Lung Cancer Research and Preventive Services Act, advances with a favorable vote in the Senate Health, Education, Labor, and Pensions (HELP) [...]
Lung cancer is one of the most common cancers in the United States, with small cell lung cancer (SCLC) making up about 15 out of every 100 (15%) cases. Like many other types of cancer, lung cancer can spread to the brain and start growing there. This is [...]
Robyn and Bob Washburn live in Simi Valley, CA where they like to spend time with family, enjoy the outdoors walking and taking hikes when they can, and go on adventures with their [...]
By Elridge D. Proctor, MPA, Senior Director, Government Affairs, GO2 for Lung Cancer Current landscape As we enter 2026, we reflect on the impact that government decisions are having on communities across the nation, especially our own, as lung cancer continues to change lives forever. [...]
A groundbreaking new open-access textbook, “Lung Cancer Navigation and Care: A Comprehensive Guide for Navigators and Allied Health Professionals,” is now available. As the first site-specific, comprehensive clinical guide for lung cancer navigation, the textbook equips navigators and allied [...]
On December 17, 2025, the U.S. Food and Drug Administration (FDA) approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for subcutaneous injection, commonly known as a shot. This approval included all the same uses of Rybrevant (amivantamab) that the FDA previously approved for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have an [...]